The tale and trials of Efgartigimod: a newly FDA approved drug for the treatment of Myasthenia gravis

Authors

  • Kashaf Waqar Fifth Year MBBS Student, CMH Multan Institute of Medical Sciences, Multan, Pakistan
  • Anika Zainab Fifth Year MBBS Student, CMH Multan Institute of Medical Sciences, Multan, Pakistan

DOI:

https://doi.org/10.47391/JPMA.6388

Abstract

Not required

Downloads

Published

2022-10-15

How to Cite

Kashaf Waqar, & Zainab, A. (2022). The tale and trials of Efgartigimod: a newly FDA approved drug for the treatment of Myasthenia gravis. Journal of the Pakistan Medical Association, 72(11), 2366–2367. https://doi.org/10.47391/JPMA.6388

Issue

Vol. 72 No. 11 (2022): NOVEMBER

Section

LETTER TO THE EDITOR